Boehringer Ingelheim and Enara Bio join forces to discover cancer immunotherapies
Agreement will leverage Enara’s novel Dark Antigen discovery platform
Read More
Tag: Dark Antigens
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
